Pharmacopeia to Present at the 15TH Annual Future Leaders in the Biotech Industry Conference
Dr. Browne's presentation will take place at 11:30 a.m. EDT on Thursday,March 27. The presentation will include an overview of the company's drugdevelopment pipeline, including an update on its internal clinical programs,PS433540 (DARA) and PS178990 (SARM). A live webcast and 90-day archive of thepresentation can be accessed at http://www.pharmacopeia.com.
Pharmacopeia is a clinical development stage biopharmaceutical companydedicated to discovering and developing novel small molecule therapeutics toaddress significant medical needs. The company has a broad portfolio ofclinical and preclinical candidates under development internally or bypartners including eight clinical compounds in Phase 2 or Phase 1 developmentaddressing multiple indications including hypertension, diabetic nephropathy,muscle wasting, inflammation and respiratory disease. The company isleveraging its fully integrated drug discovery platform to sustain the growthof its development pipeline. Pharmacopeia has established strategic allianceswith major pharmaceutical and biotechnology companies, including Bristol-MyersSquibb, Celgene, Cephalon, GlaxoSmithKline, Schering-Plough, and WyethPharmaceuticals. For more information please visit the company's website athttp://www.pharmacopeia.com.
This press release, and oral statements made with respect to informationcontained in this press release, constitute forward-looking statements withinthe meaning of the Private Securities Litigation Reform Act of 1995. Suchforward-looking statements include those which express plan, anticipation,intent, goal, contingency or future development and/or otherwise are notstatements of historical fact. These statements are based upon management'scurrent expectations and are subject to risks and uncertainties, known andunknown, which could cause actual results and developments to differmaterially from those expressed or implied in such statements. These forward-looking statements include, but are not limited to, statements about thesuccessful implementation of Pharmacopeia's strategic plans, Pharmacopeia'splans to develop PS433540, a product candidate from its DARA program,Pharmacopeia's Phase 2 and Phase 1 clinical studies with respect to PS433540,including timing and expected outcomes of such studies, Pharmacopeia's plansto develop PS178990, a product candidate from its SARM program, Pharmacopeia'sPhase 1 clinical studies with respect to PS178990, including timing andexpected outcomes of such studies, Pharmacopeia's plans to develop PS031291, aproduct candidate from its chemokine receptor CCR1 program, Pharmacopeia'sestimates of the market opportunities for its product candidates, includingPS433540, PS178990 and PS031291, Pharmacopeia's ability to successfullyperform under its collaborations with Bristol-Myers Squibb, Cephalon,GlaxoSmithKline, Schering-Plough and Wyeth, Pharmacopeia's ability to buildits pipeline of novel drug candidates through its own internally-funded drugdiscovery programs, third party collaborations and in-licensing,Pharmacopeia's ability to raise additional capital, Pharmacopeia'sexpectations concerning the development priorities of its collaborators, theirability to successfully develop compounds and its receipt of milestones androyalties from the collaborations, Pharmacopeia's anticipated operatingresults, financial condition, liquidity and capital resources, Pharmacopeia'sexpectations concerning the legal protectio
You May Also Like